Hinge Health reinstated with a buy rating and $110 price objective
HNGE•BofA Global Research reinstated coverage of Hinge Health with a buy rating and a $110 price objective.
Related News
Nasdaq trade halt continues volatility trading pause at 09:31 a.m.
AGRZ•
Steris declares R$ 0.1303324320 per unit dividend, payable Oct. 1
STE•
Piper Sandler reportedly holds talks to buy Perella Weinberg
PIPR•
Principal Financial Group announces dividend of R$2.9633333330 per unit for BRP1FGBDR 002
PFG•
Hanover Insurance declares R$ 1.6725 dividend per unit for Q3 2026
THG•